nivolumab,ipilimumab,sunitinib
bms,pfizer
['#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'cm214', 'nivo']
great point, and not only post-progression nivo was inferior, in general the post-progression treatment in cm214 was inferior comparing all io combinations trials #gu23 
Scientific Committee Member LACOG - GU. Medical Oncologist at Hospital Albert Einstein and CPO. Owner and founder BIO. Following or RT does not mean endorsement